Soleno Therapeutics (NASDAQ:SLNO) Reaches New 52-Week Low After Analyst Downgrade

Soleno Therapeutics, Inc. (NASDAQ:SLNO)’s share price reached a new 52-week low during mid-day trading on Wednesday after Oppenheimer lowered their price target on the stock from $110.00 to $80.00. Oppenheimer currently has an outperform rating on the stock. Soleno Therapeutics traded as low as $32.15 and last traded at $33.1560, with a volume of 107899 shares changing hands. The stock had previously closed at $33.62.

Several other equities research analysts also recently issued reports on the stock. Robert W. Baird set a $107.00 price objective on shares of Soleno Therapeutics in a research report on Tuesday, January 13th. TD Cowen cut their price objective on shares of Soleno Therapeutics from $120.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Wells Fargo & Company reduced their target price on shares of Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating for the company in a research note on Friday, February 27th. HC Wainwright lowered their target price on Soleno Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a report on Wednesday, March 4th. Finally, Zacks Research downgraded Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 3rd. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.54.

Key Headlines Impacting Soleno Therapeutics

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Oppenheimer kept an “outperform” rating while lowering its price target to $80, signaling continued analyst conviction in Soleno’s longer-term upside despite the cut. Oppenheimer Price Target Note
• Neutral Sentiment: Multiple firms are circulating investor alerts and reminders about a May 5, 2026 deadline to seek lead-plaintiff status, increasing visibility of the litigation but not by itself changing the legal facts; this activity typically raises short-term trading volume and news flow. Example notices include Rosen, Bernstein Liebhard, Kessler Topaz and others. Rosen Law Firm Notice
• Negative Sentiment: A securities class action has been filed alleging that Soleno made material misstatements/omissions about its Phase 3 program and that November 2025 disclosures about DCCR (VYKAT™ XR) launch disruptions harmed investors; several firms (Hagens Berman, Bronstein Gewirtz, Bernstein Liebhard, Kessler Topaz, Levi & Korsinsky, etc.) are pursuing claims. These filings elevate legal and financial risk and could pressure the stock if damages or penalties are pursued. Hagens Berman Lawsuit Notice
• Negative Sentiment: Some alerts specifically reference allegations about clinical-trial integrity and even “sham clinical trials,” which, if proven, would be materially adverse for regulatory, commercial and reputational prospects for VYKAT™ XR. Expect continued press releases from law firms and elevated volatility. SueWallSt Alert

Institutional Trading of Soleno Therapeutics

Institutional investors have recently made changes to their positions in the business. Raymond James Financial Inc. acquired a new position in Soleno Therapeutics during the second quarter worth $25,000. Danske Bank A S acquired a new stake in Soleno Therapeutics in the 3rd quarter valued at $27,000. Global Retirement Partners LLC increased its stake in Soleno Therapeutics by 519.0% in the 4th quarter. Global Retirement Partners LLC now owns 619 shares of the company’s stock valued at $29,000 after buying an additional 519 shares during the last quarter. Aster Capital Management DIFC Ltd bought a new stake in Soleno Therapeutics during the 3rd quarter worth about $37,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of Soleno Therapeutics during the 4th quarter worth about $38,000. Institutional investors own 97.42% of the company’s stock.

Soleno Therapeutics Stock Performance

The company has a market capitalization of $1.73 billion, a price-to-earnings ratio of 146.14 and a beta of -3.16. The stock’s 50 day moving average price is $39.78 and its 200 day moving average price is $50.21. The company has a current ratio of 5.80, a quick ratio of 5.55 and a debt-to-equity ratio of 0.11.

Soleno Therapeutics (NASDAQ:SLNO) last released its earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.16. The company had revenue of $91.73 million during the quarter, compared to analyst estimates of $88.55 million. Analysts expect that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current year.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.